Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y
Department of Gastroenterological Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hepatology. 2000 May;31(5):1073-9. doi: 10.1053/he.2000.6409.
To examine the role of the loss of heterozygosity (LOH) in hepatitis-related carcinogenesis, we performed a genome-wide scan of LOH in 44 tumors of hepatocellular carcinoma (HCC) using 216 microsatellite markers throughout all human chromosomes. A high frequency of LOH (>30% of informative cases) was observed at 33 loci on chromosome arms 4q, 6q, 8p, 8q, 9p, 9q, 13q, 16p, 16q, 17p, and 19p. LOH on 19p has not yet been reported, and that appears to be a new candidate in the search for tumor suppressor genes. High rates of LOH are correlated with hepatitis B virus (HBV) positivity, poorly differentiated tumors, vascular invasion, and intrahepatic metastasis (P <.0001). LOH on 13q and 16q occurred more frequently in HBV(+) patients (P <.0001), and LOH on 6q occurred more frequently in virus-negative patients (P <.001). The frequency of LOH on 4q and 13q was significantly lower in well-differentiated tumors than in moderately and poorly differentiated tumors (P <.01). In contrast, LOH on 6q was frequently detected in well-differentiated tumors compared with other histological subclasses (P <.001). Our results suggest that LOH on 6q may play an important role in the early stage of hepatocarcinogenesis in virus-negative patients, but different mechanisms might underlie the initial step to carcinogenesis in HBV(+) patients. LOH on 13q and 16q may play an essential role in the progression of HBV(+) tumors. Further studies of fine deletion mapping on chromosomes 13q and 16q are required to define the genomic segments on which putative tumor suppressor genes responsible for HBV(+) tumors exist.
为研究杂合性缺失(LOH)在肝炎相关致癌过程中的作用,我们使用遍布所有人类染色体的216个微卫星标记,对44例肝细胞癌(HCC)肿瘤进行了全基因组LOH扫描。在染色体臂4q、6q、8p、8q、9p、9q、13q、16p、16q、17p和19p的33个位点观察到高频率的LOH(>30%的信息病例)。19p上的LOH尚未见报道,这似乎是寻找肿瘤抑制基因的一个新候选区域。高频率的LOH与乙肝病毒(HBV)阳性、低分化肿瘤、血管侵犯及肝内转移相关(P<.0001)。13q和16q上的LOH在HBV(+)患者中更频繁出现(P<.0001),而6q上的LOH在病毒阴性患者中更频繁出现(P<.001)。4q和13q上的LOH频率在高分化肿瘤中显著低于中分化和低分化肿瘤(P<.01)。相反,与其他组织学亚类相比,6q上的LOH在高分化肿瘤中经常被检测到(P<.001)。我们的结果表明,6q上的LOH可能在病毒阴性患者肝癌发生的早期起重要作用,但HBV(+)患者致癌初始步骤可能有不同机制。13q和16q上的LOH可能在HBV(+)肿瘤进展中起重要作用。需要对13q和16q染色体进行精细缺失图谱的进一步研究,以确定存在负责HBV(+)肿瘤的假定肿瘤抑制基因的基因组片段。